
ImmuVen
immuven.com - Deze website is te koop! - de beste bron van informatie over immuven..
Date | Investors | Amount | Round |
---|---|---|---|
N/A | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
N/A | Acquisition | ||
Total Funding | 000k |
ImmuVen, Inc. operated as a biotechnology firm with a clear focus on developing biotherapeutics to address a range of critical health issues, including infectious diseases, cancer, and autoimmune disorders. Founded in 2007 or 2008, the company was established to capitalize on an emerging area of life science technology: high-affinity T-cell receptors (TCRs). This technology positioned ImmuVen to create a new class of immune-targeting drugs and diagnostic tools.
The company's core business revolved around its proprietary platform, which enabled the rapid selection and optimization of soluble TCRs. These receptors were engineered to target specific markers on cancer cells, pathogens causing infectious diseases, or pathways involved in autoimmune disorders. A notable application of their technology was the development of products to detect and treat Staphylococcus aureus, including the highly resistant MRSA strain, and streptococcal diseases. Their lead candidate, IMV0123, was specifically designed to combat superantigens produced by these bacteria. The firm was actively engaged in leveraging its T-cell receptor technology to create drugs for significant health problems related to viral diseases and cancer.
ImmuVen's business model was rooted in research and development, funded through a combination of venture capital and grants. The company successfully raised approximately $505,000 over three funding rounds, including a seed round in September 2010 and grants from institutions like the National Institutes of Health (NIH), the National Cancer Institute, and the National Institute for Allergy and Infectious Disease. Key investors included Serra Ventures and Fox Ventures. In December 2014, in a strategic move that underscored the value of its technology, ImmuVen was acquired by the major pharmaceutical company AbbVie. This acquisition integrated ImmuVen's promising TCR platform and its pipeline into AbbVie's broader research and development efforts in immuno-oncology and infectious diseases.
Keywords: T-cell receptors, biotherapeutics, immuno-oncology, infectious disease treatment, autoimmune disorders, AbbVie acquisition, soluble TCR platform, Staphylococcus aureus, MRSA treatment, Serra Ventures, biopharmaceutical R&D, cancer therapy, immune-targeting drugs, diagnostic agents, viral diseases, anti-bacterial therapeutics, clinical development, life science technology, molecular immunology, therapeutic agents